DSA
List the 5 signs and symptoms that EOE patients may experience.
Dysphasia, chest pain, fibrosis, food impaction and impaired quality of life
what are two known triggers
Food allergens and Aeroallergens
List the % of histologic remission for the Dupixent only arm in both part A-C and B-C
56% and 85%
How many pediatric patients were involved in Parts A and B of the clinical trial?
72
What are the treatment goals of EOE
Clinical, endoscopic, and histologic remission
Dysphasia, food impaction, and painful swallowing
What was the point reduction in EREFs score from baseline with Dupixent for parts A and A-C?
-3.2 and -4.1
What is the difference between the safety profile from the MVA vs the Clinical reprint?
>2% vs >10%
List 5 current EOE management approaches
PPIs, dilation, STC, food elimination diets, and upper EGD
What are the pathophysiological effects of EOE
Mast cell/basophil activation and degran, ephith barrier dys, remodeling and fibrosis, and eosinophilic inflammation
What is the absolute change in DSQ score at week 52 for part A-C in the placebo/Dupixent arm
-21.7
In the reprint carrier Part A-C, how many people discontinued the placebo/Dupixent arm?
5%
The HCP is not familiar with Type 2 inflammation and the role it plays in EOE.
Verbalize the inflammatory cascade, along with the signs and symptoms that patients may experience.
HCP wants to know specifically the MOA of Dupixent
Verbalize the MOA in the MVA
HCP asks how long does the EOE patient need to stay on Dupixent
Using the MVA, Verbalize the results of 24 and 52 week co-primary/secondary endpoints.
The HCP is asking about Dupixent being a biologic and the side effects that go along with it.
Using the MVA, verbalize the safety profile and important considerations